MDACC Study No:2012-0904 ( NCT No: NCT01685021)
Title:A Phase IIa, Single-Arm, Open-Label Study of MOR00208, a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Principal Investigator:Elias Jabbour
Treatment Agent:MOR00208
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the study drug MOR00208
can help to control B-ALL. The safety of this drug will also be studied.

MOR00208 is designed to attach to a protein on the surface of B-ALL cells,
which may cause them to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:MOR00208
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:MorphoSys AG
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Elias Jabbour
For Clinical Trial Enrollment:713-792-7543
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults